Introduction
THE activated insulin receptor phosphorylates various cellular substrates on tyrosine residues [1]. These substrates include the insulin receptor substrate family (IRS-1, -2, -3, -4). IRS functions as a multisite docking protein that interacts with the src homology 2 (SH2) domains of various signal-transducing molecules, including p85 subunit of PI3-kinase, Grb2, SHP2, Nck, and Fyn to propagate the insulin signal downstream [1] . Among them, PI3-kinase is a key molecule to mediate many of insulininduced metabolic signaling [1] . Shc is another substrate of the insulin receptor [1, 2] . It is so named because Shc contains a SH2 domain and a Collagenhomologous region, and is composed of an aminoterminal phosphotyrosine binding (PTB) domain, a central collagen homology (CH) domain, and a carboxyl-terminal SH2 domain ( Fig. 1) [3]. Anti-Shc antibody recognizes three distinct 46-, 52-, and 66-kDa isoforms of Shc [3] . All of these Shc isoforms originate from alternative splicing of a primary Shc transcript [3, 4] . The 46-and 52-kDa proteins are ubiquitously expressed except in the central nervous system, while the 66-kDa Shc protein is absent in some hematopoietic cells [3, 4] . These three classical Shc isoforms are also referred to collectively as ShcA [5, 6] . Two ShcA related genes, ShcB/Sck and ShcC/N-Shc, have been identified in the mouse and human [5, 6] . ShcB and ShcC are predominantly expressed in the brain, and may mediate the signaling from tyrosine kinases in the nervous system [5, 6] . In this review, we mainly describe the role of 46-, 52-, and 66-kDa Shc (ShcA) in insulin signaling.
To facilitate the understanding of the Shc function, the specific roles of various Shc domains and tyrosine phosphorylation sites have been characterized. Furthermore, the role of Shc in insulin signaling has been compared with that in EGF signaling, because EGF functions only as mitogenic factor, whereas the physiological role of insulin is mainly metabolic. residues for the MAP kinase activation [8] . Interestingly, Drosophila Shc has tyrosine residues corresponding to Tyr-239/240 residues, but not Tyr-317 residue of mammalian Shc [10] . The fact that Shc Tyr-239/240 residues are highly conserved in evolution suggests that the phosphorylation of these residues is of fundamental importance. However, tyrosine-phosphorylated Drosophila Shc does not interact with Drosophila Grb2 in flies expressing the activated Drosophila EGF receptor homologue (DER) [10] . These results indicate that the signaling pathway from Shc to Grb2 occurred in evolution mainly via Shc Tyr-317 residue rather than Tyr-239/240 residues, although Shc also develops to utilize its Tyr-239/240 residues in a minor capacity to associate with Grb2 during the evolutional process, at least, in EGF signaling.
Thus, the presence of two Grb2 binding sites in mammalian Shc protein adds to the complexity of Shc function.
To clarify the role of Shc Tyr-239/240 and Tyr-317 residues in insulin signaling, we generated Shc cDNA with Tyr-317 -~ Phe (1F), Tyr-239/240 --f Phe (2F), and Tyr-239/240/317 -~ Phe (3F) mutations [11, 12] . These mutant Shc plasmids were stably transfected into Ratl fibroblasts overexpressing insulin receptors (HIRc), and insulin signaling was compared among these cell lines. Insulin-induced tyrosine phosphorylation of Shc, Shc . Grb2 association, and MAP kinase activation were significantly decreased in 1F-Shc and 3F-Shc cells, while these events were only slightly affected by expression of 2F-Shc [11, 12] . These findings indicate that Shc Tyr-317 residue is the predominantly insulin-induced phosphorylation site compared to Tyr-239/240 for coupling with Grb2, leading to MAP kinase activation in Rat 1 fibroblasts (Fig. 2 ).
She interaction with the insulin receptor
The SH2 domain of Shc was originally shown to be a site to bind to the phosphorylated EGF receptor [3] . In this interaction, Shc appears to interact with the amino acid residues amino-terminal to phosphotyrosine of the receptor.
This interaction is uncommon for SH2 domains that usually interact with the amino acid residues carboxyl-terminal to phosphotyrosine [3] . In addition, the SH2 domain of Shc does not interact with the insulin receptor [13 , 14J. Thereafter, the phosphotyrosine-binding (PTB) domain, that is distinct from that of all members of the known SH2 domain family, was shown to be capable of binding to phosphotyrosine residues [13] [14] [15] . Although tyrosine phosphorylated EGF receptors associate with both the SH2 domain and PTB domain of Shc, the activated insulin receptor interacts with Shc only via the PTB domain (Fig. 2) [13] . This interaction via Shc PTB domain is functionally important, because disruption of insulin receptor-Shc association by cellular microinjection of Shc-PTB GST fusion protein, but not Shc-SH2 GST fusion protein, effectively inhibited insulin-induced BrdU incorporation [13] . These results are consistent with the notion obtained by using yeast two-hybrid system, demonstrating insulin receptor interaction with Shc via the PTB domain [14, 15] . Phosphorylation of Tyr-960 residue of the juxta-membrane region of the insulin receptor a-subunit is required for the interaction with Shc [14, 15] . Because the IRS family, via the PTB domain, can also interact with the j uxtamembrane domain around Tyr-960 of the insulin receptor, Shc and IRS can be considered as competitive substrates of the insulin receptor [11, 13] .
The role of p46/52-She in insulin-induced mitogenesis p2lras is a key molecule in the mitogenic signaling initiated by receptor tyrosine kinases including the insulin receptor [2, 16] . Since Grb2, an adaptor protein for the p2lras guanine nucleotide exchange factor Sos, can associate with IRS-1 independent of Shc, it is possible that insulin receptors can stimulate p2lras by interaction of IRS-1 with Grb2. Sos and that Shc is unnecessary for the signaling pathway [2, 16] . However, we demonstrated that Shc association with Grb2 . Sos represents a predominant mechanism whereby insulin activates p21 ras-MAP kinase [16] . Firstly, a larger amount of Grb2 was associated with Shc than with IRS [16] . Secondly, a significant amount of Sos activity for p2lras activation was seen in the anti-Shc immunoprecipitates, whereas only a negligible amount of Sos activity was associated with anti-IRS-1 immunoprecipitates in Rati fibroblasts expressing insulin receptors [16] . Based on these findings, the role of Shc in insulin-induced mitogenesis was proposed. To specifically identify the functional role of Shc in insulin-induced mitogenesis, we conducted single cell microinjection studies with anti-Shc antibody. The results demonstrated that microinjection of anti-Shc antibody into Ratl fibroblasts expressing insulin receptors led to an 80% inhibition of subsequent insulin-induced DNA synthesis [2] . These findings indicate the importance of Shc in the mitogenic signaling of insulin. The role of Shc was further strengthened by gain-of-function experiments [11, 12] . Overexpression of wild-type p52sn~ enhanced insulin stimulation of thymidine incorporation and BrdU incorporation.
In contrast, expression of 1F-and 3F-p52Sh~, which are dominant negative forms of Shc by inhibiting the endogenous Shc function, led to a decrease in insulin-induced DNA synthesis [11, 12] . Taken together, Shc appears to play an important role in insulin induced mitogenesis via p2lras activation. p2lras becomes active as a signaling molecule when it is converted from the GDP-to GTP-bound form, and this process is mainly controlled by Sos guanine nucleotide exchange factor for p2lras [2, 16] . The proline rich region of Sos binds to the SH3 domain of Grb2, and preformed Grb2. Sos complexes exist within unstimulated cells [2, 16] . Shc stimulates p2lras-GTP formation by interacting with the Grb2. Sos complex [16, 17] . By Shc binding to Grb2 . Sos, Sos translocates from cytosol to transmembrane, where activation of p2lras occurs [19, 20] . In addition, insulin induced formation of the Shc . Grb2 . Sos complex appears to increase the guanine nucleotide releasing activity of Sos [19] . However, prolonged p2lras activation, either by introducing oncogenic forms of p2lras or by activation of endogenous p2lras by the introduction of upstream activators such as membrane-targeted Sos, is a transforming event that plays a significant role in many malignancies [211. The pattern of p21 ras activation after insulin stimulation is a rapid increase in GTP-bound form of p2lras, peaking in the first several minutes and then falling rather rapidly toward basal levels despite ongoing insulin stimulation [21] . Thus, strict control of p2lras activation is important in growth regulation of insulin [21] . In this regard, after insulin stimulation, Sos undergoes serine/threonine phosphorylation by MEK (MAP kinase kinase) dependent pathway [21, 22] . Phosphorylation of Sos causes dissociation of Sos from Grb2, while the Shc • Grb2 complex formation is still intact [21, 22] . Thus, dissociation of Sos from Grb2 plays a key role in limiting the duration of p21 ras activation in response to ongoing insulin stimulation [21, 22] .
By these mechanisms, insulin typically causes a transient rise in p2lras activity and the subsequent fall back to basal values to attenuate the insulin signaling (Fig. 3) . . In addition, studies with general transfection techniques have difficulties to express enough amount of exogenous Shc into differentiated skeletal muscle and fat cells. For these reasons, we employed a conventional way to examine the role of Shc by employing IGF-1 as an analogous hormone in L6 myoblasts [23, 24] . By utilizing transient expression procedure with lipofectamine, overexpression of WT-Shc increased IGF-1 induced Shc association with Grb2 and MAP kinase activity, resulting in enhanced DNA synthesis in L6 cells [24] . In addition, overexpression of Shc decreased IGF-1 induced tyrosine phosphorylation of IRS because of competitive interaction as substrates of the IGF-1 receptor [24] . Since these results are consistent with the previous findings seen with insulin in Ratl fibroblasts [11, 13] , IGF-1 studies in L6 cells appear to be a useful model to analyze the impact of Shc in metabolic signaling. Interestingly, overexpression of Shc inhibited downstream signaling of IRS [24] . Thus, IGF-1 stimulation of IRS-1 association with p85 subunit of P13-kinase, PI3-kinase activity, Akt activity, and glycogen synthesis were all reduced by overexpression of Shc [24] . Furthermore, expression of Shc-PTB domain alone also inhibited IGF-1-induced tyrosine phosphorylation of IRS-1, Akt activity, and glycogen synthesis [24] . Taken together, Shc appears to inhibit IGF-1 induced metabolic signaling through inhibition of IRSmediated IGF-1 signaling.
Although the findings seen with IGF-1 may not completely apply to the signaling system in insulin's metabolic action, because of the similarities of signaling system between insulin and IGF-1, Shc may not be required for acute regulation of the metabolic actions of insulin. Shc associates with a number of membrane receptor tyrosine kinases and non-membranous intracellular tyrosine kinases such as Src [3, 4] . Furthermore, Shc has been reported to associate with several other downstream signaling molecules in addition to Grb2 (Fig. 4) [25] [26] [27] [28] [29] [30] . PEST protein tyrosine phosphatase is one such molecule and is the ubiquitously expressed cytosolic protein tyrosine phosphatase (PTPase) that is characterized by the presence of Pro, Glu, Ser, and Thr-rich PEST domains within the carboxyl terminus [25, 26] . Tyrosine phosphorylation, controlled by the coordinated actions of protein tyrosine kinases and phosphatases, is a crucial control mechanism for numerous physiological processes [25, 26] . PEST tyrosine phosphatase is one of the PTPases to regulate such signaling events, although substrate specificities of the PEST tyrosine phosphatase remain to be elucidated [25, 26] . PEST tyrosine phosphatase is known to associate with Shc, and two serine residues at positions 5 and 29 in the amino terminus of Shc are suggested to be the sites regulating binding to the PEST-tyrosine phosphatase [25, 26] . In contrast, overexpression of OSH2-SHIP 1 only minimally affected these events of insulin signaling [29] . SHIP2, which is an isozyme of SHIP1, is abundantly expressed in insulin responsive tissues, and only a small amount of SHIP 1 is expressed in these cells [29, 30] . Therefore, the results with SHIP 1 overexpression appear to indicate the role of SHIP2.
In accordance with this assumption, overexpression of SHIP2 also inhibited insulin-induced Shc • Grb2 association and MAP kinase activation [30] . Therefore, Shc and SHIP2 appear to compete for the limited pool of Grb2 in mediating insulin- Shc has been shown to be a key molecule of growth promotion and gene expression by growth factor receptors including insulin and IGF-1 receptors [2, 23] . Since previous studies have suggested the relationship between intrauterine growth retardation and glucose intolerance or type 2 diabetes occurring later in life, functional abnormalities in Shc protein are considered to be a possible candidate for a certain population of type 2 diabetes [31] . Seventy patients with type 2 diabetes mellitus were screened to examine the genetic abnormality of Shc by single stranded conformation polymorphism-heteroduplex analysis. Subsequent nucleotide sequence analysis demonstrated the existence of Met to Val mutation at codon 300 (numbered according to the 52 kDa Shc; Fig. 1) [31 ] . This mutation is assumed to exist in all three Shc isoforms [31] . Because this variant is placed in the vicinity of the tyrosine residue at Tyr-317, which is critical for insulin-induced tyrosine phosphorylation of Shc for interaction with Grb2, the impact of the heterozygous mutation of Shc has been considered [31] . However, the allelic frequencies of Met to Vat-300 polymorphism in the middleaged type 2 diabetes and age-matched glucose-tolerant subjects were not significantly different [31] . In addition, the serum insulin and C-peptide responses obtained during the oral glucose tolerance test showed no significant differences between wild-type and heterozygous carriers.
Furthermore, insulin sensitivity estimated by Bergman's minimal model and the acute insulin response examined by an intravenous glucose tolerance test in combination with intravenous injection of tolbutamide were not different between heterozygous and wild-type carriers [31] . Although transfection experiments have not been performed to exclude a minor biological impact of this Shc mutation, this mutation of Shc does not appear to be related to the pathogenesis of type 2 diabetes mellitus.
possess a unique amino-terminal CH2 region (Fig. 1 ) [4J. Like p52Shd/p46s w, p66shC becomes tyrosine phosphorylated upon activation of EGF receptors, and forms the complex with Grb2 adaptor protein [4] . However, p66Shc does not affect EGF stimulation of MAP kinase activity and inhibits c-fos promoter activation [4] . The role of p66sh~ in EGF receptor mediated MAP kinase-fos signaling is in contrast to the effect of p52Sn~/p46Sn~ [4] . In this regard, in addition to tyrosine phosphorylation of the p66Shc, p52shc, and p46Shc isoforms, EGF treatment resulted in serine phosphorylation of only the p66sh~ isoform [32, 33] . Serine phosphorylation of p66sh~ appeared to impair the ability to interact with the EGF receptor and acts in a dominant-interfering fashion by inhibiting EGF receptor downstream signaling pathway [4, 33] . Recently, the role of p66Sh~ in stress responses has been elucidated [34] . Unlike EGF, p66shc is not tyrosine phosphorylated by treatment with ultraviolet light (UV) or perhydroxyl oxide (H2O2) [34] . However, UV and H2O2 as well as EGF provoked phosphorylation of p66S w on the serine residue [34] . By targeted disruption of p66sh~, cells lacking p66Sh~ were shown to be more viable and protected from apoptosis triggered by treatment with UV or H2O2 [34] . As a result, p66Shc null mice are resistant to oxidative stress in vivo, and have increased life span [34] . Although the unique roles of p66sh~ have been identified in EGF stimulation and stress responses, insulin treatment does not elicit apparent tyrosine phosphorylation of p66Shc [2, 32] . Based on these results, it is unlikely that p66shc is directly involved in the regulation of insulin induced MAP kinase activation.
However, insulin also stimulates serine phosphorylation of p66Sh~ but not the p52Sw [35] . Serine phosphorylation of p66Shc appears to be a mechanism dependent on MEK, but not the MAP kinase pathway [35] . Further investigation of the role of p66Shc in insulin signaling and the modulation by serine phosphorylation is needed. ] . In contrast, Shc does not appear to be directly involved in metabolic signaling of insulin such as glucose uptake and glycogen synthesis, while the IRS mediated PI3-kinase pathway plays a key role in such action as insulin's metabolic effects [24] . Although direct involvement of Shc in insulin's metabolic signaling was found to be negligible, Shc may indirectly modify the signaling mediated by the IRS-P13-kinase pathway. Along this line, a direct interaction between Shc and IRS-1 has been reported in vitro [36] . In addition, Shc-interacted SHIP2 may downregulate P13-kinase product, because SHIP2 has a 5'-phosphatase activity toward PtdIns(3,4,5)P3
[30]. These possible mechanisms by which Shc regulates IRS-P13 kinase pathway for metabolic action of insulin remain to be elucidated. Recent studies with knockout mouse have shown interesting results, with the tissue-specific knockout of the insulin receptor in pancreatic R cells leading to a decrease in islet size in the older knockout mice [37] . This finding suggests that insulin signaling leading to islet /3-cell growth is related to the amount of insulin for maintenance of glucose homeostasis. In this regard, it is interesting to consider that Shc may be involved in islet j3-cell growth. This issue also remains to be elucidated. Both tyrosine-phosphorylated Shc and IRS can bind to Grb2, but Shc • Grb2 • Sos is the predominant coupling pathway from the activated insulin receptor to p21 ras. Along this line, microinjection of anti-Shc antibody inhibited insulin-induced mitogenesis, and the guanine nucleotide exchange activity for p2lras is tightly associated with Shc, but not with IRS. On the other hand, insulin only transiently activates p2lras for the strict hormonal regulation. For this regulation, longer time of insulin treatment deactivates p2lras by dissociation of Sos from the Shc • Grb2 • Sos complex while Shc is still complexed with Grb2. Thus, Shc plays a critical role in insulin-induced mitogenesis through regulation of p21 ras activity. As regards the impact of Shc on the metabolic aspects, Shc is shown to compete with IRS as the substrate of the insulin receptor. Thus, IRS mediated downstream signaling leading to glycogen synthesis was decreased by overexpression of Shc. Taken together, Shc appears to play an important role in insulin induced mitogenesis, whereas Shc may not be required for regulation of the metabolic aspects of insulin.
